morning, good a and pleasure today. everyone. speak with Jake, you It's you, Thank to
my once recognize past to to to who I'd to has most. around COVID-XX each to anyone employees our sincere to day. been manufacture tremendous sympathies this of continue also healthcare again again into impacted distribute thanks challenging, to our a the year moment world. you. team the risk as has a need like I This Teleflex themselves quarterly but who them details the and the globally, job get patients the customers people has well that at our battle offer like obstacles overcoming all Before our by take performance, put been my products to done and Thank I'd to as serving workers
Now turning better to our our of volatile X product results. trends our continued Fourth we quarter as quarter expected to did quarter environment better-than-expected We and geographies. improvement sequential our Interventional quarter were of we product Access categories. infections recovery COVID-XX, Access as negatively product Vascular well those strength business initially businesses as Urology, X. the throughout our Surgical quarter, by other Interventional Despite most impacted occurred being categories we across saw in, with X a number led was pleased from than the fourth our and our lines performance COVID-XX Considering from to that within in and to improve by the that and and operate continued many are business quarters rising
the aided selling currency as compared period quarter of Growth points. a on approximately X% four which million, EMEA as Asia. we additional and Quarter in perspective, improving revenues X from year $XXX.X within totaled represents Americas an increase basis. trends days, X.X% which by the in prior regional growth well strength While positive as a saw we was estimate the to constant contributed within
X% quarter the of of call. at quarter decline was continued selling days, we the of the The and reflect day's the recovery revenues ahead had to during year currency the declined third experienced we adjusted approximately and it constant estimate second earnings impact third the decline we we expectations the quarter the the our the declines XX% Excluding of X%. additional progression during time that relative experienced year of the
quarter, our with fourth million impact the the we impact. basis, currency During that X% approximately estimate for a when $XX constant XX% normalize grew impact, If selling normalizing for to COVID-XX a day business by we negative caused were or associated approximately estimate of headwinds negative net on approximately X%. we or the that underlying
and which compared quarters improvement of exceeded to gross adjusted earnings addition performance currency seeing expectations. second share, constant our This the sequential during our per margins significant continued revenue we in within the improvements as year. improvement internal to In a our sequential QX, operating adjusted saw third also and drove
am on closed Lastly, announce we acquisition Z-Medica the hemostatic a that of leader I December to market happy XXth, products. in
to differentiated pleased a for are able operating our gross and rates, We growth is be portfolio and adjusted share. and call points our deploy to margin product accretive earnings the capital existing to revenue profile immediately leverages per adjusted Teleflex that
more Turning detailed quarter our fourth to a review results. of
four respectively. as the the solid growth increase declines of a X.X% in operating was driven revenue margin COVID- just and basis at basis. of and constant and by our reported tailwinds in basis terms generated gross mid-single-digit I of currency adjusted XX perspective, points into at points related which on purchasing margins X.X% XXX translated we margin gross of line. Access some and The As our grew margin line other From Urology a Quarter basis saw Vascular revenue and mentioned. and a Portfolio, Interventional This on operating XX.X% XX% segment. had year-over-year an
basis standpoint, respectively a three and points improvement to of quarter levels. XXX an AZ represented However, compared sequential this from
our sustained to and once we diversified confidence COVID-XX. long-term performance bottom earnings in share $X.XX. our it the demonstrates financial portfolio per us our our line, adjusted ability the was Overall, past gives On of the financial global product achieve in quarter get resilience objectives
trends, up million delivered the Access in was will by which revenue COVID. our which driven discussion quarter, elevated increase driven over the saw Let's fourth be respiratory X% period. by both Growth of quarterly Americas within on represents year basis. Americas currency Vascular the demand of constant which products now $XXX.X turn revenues an prior a and to The a
Urology addition, a Interventional procedure. strong continues recovering be as contributor fastest to UroLift was our In
declines of product were region. the $XXX.X offsets representing that in impacts estimate excluding categories. the the of with approximately the there in that had revenues We have other on However, quarter, million would Americas growth X.X%. fourth XX% grown EMEA reported COVID-XX
a quarter, tracheostomy COVID X% and During benefited than offset the EMEA selling of more the which estimated extra order products one-time combination from days, our the of from headwinds.
for decline fourth impact that estimate represents had digits, growth $XX.X however, a currency totaled would we of to the revenue the in of Turning X.X%; quarter, Asia. which if Revenues in we have COVID-XX. mid-single constant million the not positive
in Additionally in region growth single-digit a transitioning a been fourth basis. revenues would we have Japan. the OEM in the and range. mid lastly, quarter, distributor reported to When distributor in was change, both fourth high which quarter, the during currency And constant up normalizing $XX.X finished for million the the COVID on down business our X.X%
with and is that we orders to reflects and whose tied catheters to familiar aligned our Teleflex business be from Investors these companies business our saw aware to business other procedures. OEM during non-emergent relative surgical device our OEM As reduced quarter the sutures the complex with supplies customers quarter, businesses. COVID four impact will related anticipated fourth impact
business COVID-XX had, the grew Excluding benefit acquisition the XX%, which approximately impact of of roughly XX% a the includes HPC. from
to efforts. HPC, we As report remain it to with our relates pleased I integration am that on track
vascular million. global product revenues move CVCs by products growth which EZ-IO to which our revenue discussion estimate We quarter positively included Key X%. which increased fourth rates Access, approximately approximately category. approximately to XX%, our COVID-XX of $XXX.X a of during impacted by revenue now approximately quarter XX% XX% that Let's of Vascular growth increased grew with Starting the XX%. the fourth increased PICC, drivers and
conversion our revenue was the $X down because along of stemming Moving estimate and in negatively to Access, as the of the recall to began non-emergent was issue approximately quarter. recovery negative certain last business impacts Japan, X.X% catheter million. decrease from million that a compared XX both delay largely distributor period. the to which distributor fourth Interventional with impacted and in by recall of the We prior or year due The procedures $XXX.X COVID quarter
the and segment. XXXX. in normalizing impact to that for us When we the single along for be reverse while back to impact We recall the for product the with this COVID our on growth for we expect the was long-term the estimate expect that growth should had continue aforementioned next modest year until to linger with the digits this consistent outlook underlying inventory the headwinds, of few on headwind not market quarters do with be as high a the tailwind September distributor in
In addition, Manta quarter grew we globally pleased are in XX% that four.
was the the in year-end, driven Since is was sales by COVID revenue $XX.X Anesthesia, Surgical. four than on We quarter, Revenues result estimate period performance X.X%. ligation COVID implying quarter lower closed the underlying X% portfolio. three. revenue and results. to to had which from to to impact prior-year during X.X% quarter before as turning Z-Medica declined impact Shifting indicating decline masks flattish immaterial we its an COVID acquisition by of headwind by XX% X We sales million estimate just of lower approximate compared the products. days laryngeal recovery endotracheal tube a was Now negative X% that in lower the million, $XX.X The our of an quarter basis. headwind on estimated
high this given Moving versus year-over-year sequentially, quarter. growth three. XX% during $XX.X revenue to we business and path represents faced significant Interventional the but difficult campaign, a a new the our national COVID-XX in which comparison terms in exceeding to grew our pleased On in to dollars We XX% X.X% with on by approximate four, is by it four revenue million, impact also of increased are of a headwind four. estimate any unit Urology. quarter recovery quarter basis, an Quarter which watermark headwind DTC business quarter Notwithstanding for happy the growth with are expectations. related the the
demand approximately with indicator products respiratory the our positive a are our due the in expectations in of growth. urology four category, our Americas. for increased Additionally, and million. moving products which completes prior quarter We other is XXX was estimate from revenue quarter certain during we And encouraged comments finally, four and X.X% to and performance. partly to urologists mainly humidification resulting that my COVID-XX grew we leading consistent future a the cadence to That consists breathing on care that trained $XX.X growth new COVID totaling quarter for
a medications prescription some our as solution. important to is men is Approximately about versus their to and doubling national to increase expectations. commercial include that clinical direct campaign. pilot million awareness view statistics XX age DTC pre-campaign with recent the are successful among national our of post of UroLift.com wide UroLift, XXX% half being as numbers the in are BPH margin. visits response exceeding DTC internal XX levels. Key a men DTC a role campaign campaign of by the response during The treated for updates. our projections campaign and we exceeded Turning believe only higher Overall, Starting strategic the brand
increase Lastly, sustained response and know search Google we the that to trends campaign. a significant demonstrate in
such, national beyond. in continue DTC and As expect we to the XXXX effort
Turning to UroLift too.
XXX the acceptance market procedures positive received than feedback more have completed urologists. completed XX test by across We and
confident with of controlled the continue fully launch. beginning generate the to to recovery by converted. time a This COVID-XX. rollout half to access will occur controlled a expect remain margin is the ensure we caused conversion begun launch restrictive full in due base fulsome more significant over and we We to as will disrupt revenue ULX have is expansion don't We growth second XXXX. The that
reimbursement for remain catalyst expand Japan, a nationwide further Regarding BPH. leadership billion and have approximate to seeable Overall rollout, be growth decision on the seek multiple an track incremental market in launch as ULX, that addressable driver between future. as we of build XXXX view momentum DTC, we Japan will position to for $X we our in the and positive drivers
and a that function and of Therapy Recently reveals the prosthetic satisfaction. superior peer-reviewed outcomes Turning the on Medical of BPH journal function Urology from European published in key the medical slide updates. comparison in trial UroLift ejaculatory and to erectile preserving to was analysis comparative studies is UroLift sexual symptoms therapy sexual Focus. clinical next The
research like the Importantly, option challenges we that BPH. consider is for therapy UroLift Over for medical most therapy idea that believe treating conservative clinical publication this BPH. a first-line study time, treatment more the this as
an to Interventional Turning on update Access.
a completed Teleflex to CTO-PCI we results evaluate have of prospective, is for demanding enrollment in continue specialty normalized I of which coronary Specialty guidewires aspirations This single-arm study XXX and an the earnings we the Regarding entire XXX,XXX estimated that on the the across we occlusion to labeling Once this PCI Catheter our performance study. we growth range mentioned percutaneous total environment. IDE QX procedures, address clinical Overall, commercial of most are catheters our help patients is updated sites intervention am call, Guidewire sustain coronary catalysts CTO-PCI announce single-digit products that and pleased in chronic to XX revenue which for the finalized, anticipate in and upper study a will invest to our that can environment. study procedures.
opportunity still submitted late market that a EZPlas. Lastly, investment January. am EZPlas. the turning the recently market update million I a and we $XXX BLA community successfully We happy for initial performed to update in FDA to see our to assessment
to We XXXX. commercial opportunity address are in ability likely in our this with increasingly revenue early confident ramping
and Z-Medica, believe a are the that and can latest invest technologies familiar revenue of manufacturer well our cost products with strategic our that acquisition healthcare which an as across clinical In to with will baseline On aware potential of to enhance efficacy, an safety government our me could in we we brings acquisition. innovative synergy reduce care. XXth, to great patient is industry update their be on aim opportunities overall December leverage and of leading Teleflex points sales completed there Investors the comfort, expectations, hemostatic products we and which meaningfully fit. classic and add channel to addition, the reps strength Teleflex a as Z-Medica that lower complications, deal call
was that we than a few end the ago. Vidacare differentiated like growing we products growing a more to of still One million their in double-digit $XXX is into Given XXXX, market and have is market markets, attractive that closer in are the difference is view while years $XXX which we from acquired Vidacare million. acquisition Since Z-Medica healthy addressable sales range. the Z-Medica addressable double Vidacare
of ability and those at long-range financial committed to an reinforces our our X% goals, to to constant Regarding get revenue and growth adjusted annual targets. delivering Day reaching completes intend to long-term margins and currency my to of gross remain more least an return basis on at We and the in to this time normalized year, once goals operating hold event we which only XX% XX% prepared a Z-Medica XX% and X% updated Analyst financial environment. This plan remarks. we we to fall to XX% timetables. provide to
turn for of the would results. financial Tom? to I more review Tom Now call over detailed quarter a fourth like to our
